BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 18515870)

  • 1. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
    Leite MI; Jacob S; Viegas S; Cossins J; Clover L; Morgan BP; Beeson D; Willcox N; Vincent A
    Brain; 2008 Jul; 131(Pt 7):1940-52. PubMed ID: 18515870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple antibody detection in 'seronegative' myasthenia gravis patients.
    Hong Y; Zisimopoulou P; Trakas N; Karagiorgou K; Stergiou C; Skeie GO; Hao HJ; Gao X; Owe JF; Zhang X; Yue YX; Romi F; Wang Q; Li HF; Gilhus NE; Tzartos SJ
    Eur J Neurol; 2017 Jun; 24(6):844-850. PubMed ID: 28470860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
    Koneczny I; Cossins J; Waters P; Beeson D; Vincent A
    PLoS One; 2013; 8(11):e80695. PubMed ID: 24244707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.
    Farrugia ME; Bonifati DM; Clover L; Cossins J; Beeson D; Vincent A
    J Neuroimmunol; 2007 Apr; 185(1-2):136-44. PubMed ID: 17335909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
    Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
    J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis.
    Damato V; Spagni G; Monte G; Woodhall M; Jacobson L; Falso S; Smith T; Iorio R; Waters P; Irani SR; Vincent A; Evoli A
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):995-1000. PubMed ID: 35835469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of clustered-AChR for the detection of SNMG.
    Zhao G; Wang X; Yu X; Zhang X; Guan Y; Jiang J
    Sci Rep; 2015 Jun; 5():10193. PubMed ID: 26068604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features.
    Park KH; Waters P; Woodhall M; Lang B; Smith T; Sung JJ; Kim KK; Lim YM; Kim JE; Kim BJ; Park JS; Lim JG; Kim DS; Kwon O; Sohn EH; Bae JS; Yoon BN; Kim NH; Ahn SW; Oh J; Park HJ; Shin KJ; Hong YH
    PLoS One; 2018; 13(3):e0193723. PubMed ID: 29518096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
    Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
    Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.
    Leite MI; Ströbel P; Jones M; Micklem K; Moritz R; Gold R; Niks EH; Berrih-Aknin S; Scaravilli F; Canelhas A; Marx A; Newsom-Davis J; Willcox N; Vincent A
    Ann Neurol; 2005 Mar; 57(3):444-8. PubMed ID: 15732104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia gravis seronegative for acetylcholine receptor antibodies.
    Vincent A; Leite MI; Farrugia ME; Jacob S; Viegas S; Shiraishi H; Benveniste O; Morgan BP; Hilton-Jones D; Newsom-Davis J; Beeson D; Willcox N
    Ann N Y Acad Sci; 2008; 1132():84-92. PubMed ID: 18567857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.
    Zisimopoulou P; Evangelakou P; Tzartos J; Lazaridis K; Zouvelou V; Mantegazza R; Antozzi C; Andreetta F; Evoli A; Deymeer F; Saruhan-Direskeneli G; Durmus H; Brenner T; Vaknin A; Berrih-Aknin S; Frenkian Cuvelier M; Stojkovic T; DeBaets M; Losen M; Martinez-Martinez P; Kleopa KA; Zamba-Papanicolaou E; Kyriakides T; Kostera-Pruszczyk A; Szczudlik P; Szyluk B; Lavrnic D; Basta I; Peric S; Tallaksen C; Maniaol A; Tzartos SJ
    J Autoimmun; 2014 Aug; 52():139-45. PubMed ID: 24373505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seronegative myasthenia gravis.
    Vincent A; McConville J; Farrugia ME; Newsom-Davis J
    Semin Neurol; 2004 Mar; 24(1):125-33. PubMed ID: 15229799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.
    Takata K; Stathopoulos P; Cao M; Mané-Damas M; Fichtner ML; Benotti ES; Jacobson L; Waters P; Irani SR; Martinez-Martinez P; Beeson D; Losen M; Vincent A; Nowak RJ; O'Connor KC
    JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
    Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
    Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.
    Plested CP; Tang T; Spreadbury I; Littleton ET; Kishore U; Vincent A
    Neurology; 2002 Dec; 59(11):1682-8. PubMed ID: 12473752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies in myasthenia gravis and related disorders.
    Vincent A; McConville J; Farrugia ME; Bowen J; Plested P; Tang T; Evoli A; Matthews I; Sims G; Dalton P; Jacobson L; Polizzi A; Blaes F; Lang B; Beeson D; Willcox N; Newsom-Davis J; Hoch W
    Ann N Y Acad Sci; 2003 Sep; 998():324-35. PubMed ID: 14592891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.